Murat ÇAP, Bernas ALTINTAŞ, Önder BİLGE, Ferhat IŞIK, Ümit İNCİ, Rojhat ALTINDAĞ, Abdurrahman AKYÜZ, Muhammed SÜLEYMANOĞLU, Burhan ARSLAN, İlyas KAYA, Mehmet Şahin ADIYAMAN, Derya Deniz ALTINTAŞ, Neşe KANBAL, Erkan BAYSAL

Electrolyte Imbalance and Its Effect on QTc Interval in Patients Hospitalized with COVID-19

Objective: Studies have shown that electrolyte abnormalities can be seen in Coronavirus disease 2019 (COVID-19) patients and are associated with the severity of the disease. We aimed to investigate the electrolyte imbalance such as hypocalcemia and hypokalemia in patients hospitalized with COVID-19 and its effect on the QTc interval. Materials and Methods: 185 hospitalized patients with COVID-19 whose diagnosis was confirmed by a real-time reverse transcriptasepolymerase chain reaction and/or Computed Tomography of the chest were included in the study. The potassium and calcium measurements on the admission and third day of hospitalization were recorded. The QTc interval measurement was performed on the admission (QTc-B) and the 3rd-day (QTc-AT) electrocardiography. Results: The median age was 43 (31-56 IQR) and 102 (55.1%) of patients were male. Median baseline potassium level was 4.0 mEq/L (3.7-4.3 IQR) and corrected calcium level was 8.48 mg/dl (8.24-8.73 IQR), whereas the 3rd-day median potassium level was 4.2 mEq/L (3.9-4.5 IQR) and corrected calcium level was 8.42 mg/dl (8.16-8.70 IQR).The median QTc-B interval was found as 427 ms (409-447 IQR) whereas the median QTc-AT interval was found as 438 ms (414-459 IQR). Median 9 ms (-5- 28 IQR) prolongation was observed in the QTc interval, which was statistically significant (p

PDF

___

[1] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-1242.

[2] World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. https://www.who.int/dg/speeches/detail/ who-directorgeneral-s-opening-remarks-at-the-mediabriefing-on-covid19—11-march-2020. Accessed March 24, 2020.

[3] World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). https://www.who. int/news-room/detail/30-01-2020-statement-on-thesecond-meeting-of-theinternational-health-regulations- (2005)-emergency-committee-regarding-the-outbreakof-novel-coronavirus-(2019-ncov). Accessed March 24, 2020.

[4] Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. Published online March 27, 2020. doi:10.1001/jamacardio.2020.1286

[5] Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006; 47:362-7.

[6] Zhang Y, Post WS, Dalal D, et al. QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2011; 171: 1727-33.

[7] Beinart R, Zhang Y, Lima J, et al. The QT interval is associated with incident cardiovascular events: the MESA study. J Am Coll Cardiol. 2014; 64: 2111-9.

[8] Chorin E, Wadhwani L, Magnani S, et al. QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin [published online ahead of print, 2020 May 11]. Heart Rhythm. 2020; S1547-5271(20)30435-5.

[9] World Health Organization. The cardiotoxicity of antimalarials: Malaria Policy Advisory Committee Meeting. Published March 24, 2017. Accessed April 21, 2020. https://www.who.int/malaria/mpac/ mpac-mar2017-ergcardiotoxicity-report-session2.pdf

[10] Ray WA, Murray KT, Hall et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366(20): 1881- 1890.

[11] Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708-1720.

[12] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506.

[13] Lippi G, South AM, Henry BM. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Ann Clin Biochem. 2020; 57(3): 262‐265

[14] Chen, D, Li, X, Song, Q, et al. Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). medRxiv. Epub ahead of print 29 February 2020. doi:10.1101/2020.02.27.20028530

[15] El-Sherif N, Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J. 2011; 18(3): 233‐245.

[16] Tisdale JE, Jayes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013; 6: 479-487.

[17] Gulhar R, Jialal I. Physiology, Acute Phase Reactants. [Updated 2020 Mar 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519570/

[18] Payne RB, Little AJ, Williams RB, et al. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973; 4(5893): 643‐646.

[19] Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab. 2009; 27(6): 635‐642.

[20] Kardalas E, Paschou SA, Anagnostis P, et al. Hypokalemia: a clinical update. Endocr Connect. 2018; 7(4): R135‐R146.

[21] Huang C, Wang Y, Li X, Ren L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020.

[22] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507-13.

[23] Min Cao, Dandan Zhang, Youhua Wang, et al. ; Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China medRxiv 2020.03.04.20030395

[24] Liu, Y, Yang, Y, Zhang, C, et al. : Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020; 63: 364-374.

[25] Kelly A, Levine MA. Hypocalcemia in the critically ill patient. J Intensive Care Med. 2013; 28(3): 166‐177.

[26] Mercuro NJ, Yen CF, Shim DJ, et al. ; Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 May 1]. JAMA Cardiol. 2020; e201834. doi:10.1001/ jamacardio.2020.1834

[27] Eryol NK, Colak R, Ozdogru I, et al. ; Effects of calcium treatment on QT interval and QT dispersion in hypocalcemia. Am J Cardiol. 2003; 91: 750-2.

[28] Bronsky D, Dubin A, Waldstein SS, et al. Calcium and the electrocardiogram. I. The electrocardiographic manifestations of hypoparathyroidism. Am J Cardiol. 1961; 7: 823-32

[29] Weiss JN, Qu Z, Shivkumar K. Electrophysiology of Hypokalemia and Hyperkalemia. Circ Arrhythm Electrophysiol. 2017; 10(3): e004667. doi:10.1161/ CIRCEP.116.004667

[30] Keihani Douste Z, Haghi Ashtiani MT, Shariat M, et al. Comparative Evaluation of Corrected QT and Ionized Calcium in Children. Acta Med Iran. 2015; 53(9): 579‐581.

[31] Simpson TF, Kovacs RJ, Stecker EC. Ventricular arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19. March 29, 2020. Available at: https://www. acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ ventriculararrhythmia-risk-due-to-hydroxychloroquineazithromycin-treatment-for-covid-19

[32] The European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. https://www.escardio.org/ Education/COVID-19-and-Cardiology/ESC-COVID-19- Guidance. (Last update: 28 May 2020)